Retina specialists discuss therapies that promise to reduce the treatment burden of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) through extended durability. They also highlight the latest clinical data on the efficacy and safety of these therapies.
Rishi P. Singh, MD, and M. Ali Khan, MD, FACS, FASRS, discuss the need for extending treatment durability for neovascular age-related macular degeneration [nAMD] and diabetic macular edema [DME], as well as approaches to applying treat-and-extend strategies.
Drs Rishi P. Singh and M. Ali Khan review the real-world experience of using faricimab to treat nAMD and DME, as well as its durability compared to clinical trials.
M. Ali Khan, MD, FACS, FASRS, reviews the PULSAR and PHOTON clinical trials of high-dose aflibercept for treatment of nAMD and DME.
Retina specialists highlight the safety data of both faricimab and high-dose aflibercept for use in treating nAMD and DME.
Retina specialists comment on switching patients from 2 mg to 8 mg of aflibercept for the management of neovascular age-related macular degeneration and diabetic macular edema and transitioning a patient who has good control with aflibercept to a newer therapy.
Retina specialists discuss factors to consider when selecting a therapy for patients with neovascular AMD and DME as well as loading-dose recommendations for select patients.
Retina specialists discuss treatment and adherence strategies for patients with nAMD and DME. They also comment on the future of nAMD and DME management.
